메뉴 건너뛰기




Volumn 10, Issue 2, 2014, Pages 211-217

Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: Implications for MET targeting in oncology

Author keywords

ALK; crizotinib; ID1; lung cancer; MET; migration

Indexed keywords

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES;

EID: 84893856319     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.179     Document Type: Article
Times cited : (6)

References (31)
  • 1
    • 44849093562 scopus 로고    scopus 로고
    • Oncogene addiction
    • discussion 80
    • Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 68, 3077-3080; discussion 80 (2008).
    • (2008) Cancer Res. , vol.68 , pp. 3077-3080
    • Weinstein, I.B.1    Joe, A.2
  • 2
    • 78649760112 scopus 로고    scopus 로고
    • Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma
    • Bronte G, Rizzo S, La Paglia L et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat. Rev. 36(Suppl. 3), S21-S29 (2010).
    • (2010) Cancer Treat. Rev. , vol.36 , Issue.SUPPL. 3
    • Bronte, G.1    Rizzo, S.2    La Paglia, L.3
  • 3
    • 77952965634 scopus 로고    scopus 로고
    • ALK, lung cancer, and personalized therapy: Portent of the future?
    • Garber K. ALK, lung cancer, and personalized therapy: portent of the future? J. Natl Cancer Inst. 102, 672-675 (2010).
    • (2010) J. Natl Cancer Inst. , vol.102 , pp. 672-675
    • Garber, K.1
  • 4
    • 79960042770 scopus 로고    scopus 로고
    • Targeted therapy in non-small-cell lung cancer-is it becoming a reality?
    • Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat. Rev. Clin. Oncol. 7, 401-414 (2010).
    • (2010) Nat. Rev. Clin. Oncol. , vol.7 , pp. 401-414
    • Janku, F.1    Stewart, D.J.2    Kurzrock, R.3
  • 5
    • 84859508816 scopus 로고    scopus 로고
    • ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development
    • Scagliotti G, Stahel RA, Rosell R et al. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur. J. Cancer 48, 961-973 (2012).
    • (2012) Eur. J. Cancer , vol.48 , pp. 961-973
    • Scagliotti, G.1    Stahel, R.A.2    Rosell, R.3
  • 8
    • 70350140489 scopus 로고    scopus 로고
    • Clinical activity observed in a phase i dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066
    • Abstract 3509
    • Kwak EL, Camidge DR, Clark J et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J. Clin. Oncol. 27(Suppl.), Abstract 3509 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , Issue.SUPPL.
    • Kwak, E.L.1    Camidge, D.R.2    Clark, J.3
  • 9
    • 78049425319 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    • Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
    • (2010) N. Engl. J. Med. , vol.363 , pp. 1693-1703
    • Kwak, E.L.1    Bang, Y.J.2    Camidge, D.R.3
  • 10
    • 80053386829 scopus 로고    scopus 로고
    • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis
    • Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12, 1004-1012 (2011).
    • (2011) Lancet Oncol. , vol.12 , pp. 1004-1012
    • Shaw, A.T.1    Yeap, B.Y.2    Solomon, B.J.3
  • 11
    • 84872569905 scopus 로고    scopus 로고
    • Phase III Study of Crizotinib versus Pemetrexed or Docetaxel Chemotherapy in Patients with advanced ALK-positive Non-Small Cell Lung Cancer (NSCLC) (PROFILE 1007)
    • Abstract LBA1-PR
    • Shaw AT, Kim DW, Nakagawa K et al. Phase III Study of Crizotinib versus Pemetrexed or Docetaxel Chemotherapy in Patients with advanced ALK-positive Non-Small Cell Lung Cancer (NSCLC) (PROFILE 1007). Ann. Oncol. 23(Suppl. 9), Abstract LBA1-PR (2012).
    • (2012) Ann. Oncol. , vol.23 , Issue.SUPPL. 9
    • Shaw, A.T.1    Kim, D.W.2    Nakagawa, K.3
  • 12
    • 80052969848 scopus 로고    scopus 로고
    • MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential anti-tumor effects in non-small cell lung cancer according to MET alterations
    • Tanizaki J, Okamoto I, Okamoto K et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential anti-tumor effects in non-small cell lung cancer according to MET alterations. J. Thorac. Oncol. 6, 1624-1631 (2011).
    • (2011) J. Thorac. Oncol. , vol.6 , pp. 1624-1631
    • Tanizaki, J.1    Okamoto, I.2    Okamoto, K.3
  • 13
    • 79955458487 scopus 로고    scopus 로고
    • Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification
    • Ou SH, Kwak EL, Siwak-Tapp C et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J. Thorac. Oncol. 6, 942-946 (2011).
    • (2011) J. Thorac. Oncol. , vol.6 , pp. 942-946
    • Ou, S.H.1    Kwak, E.L.2    Siwak-Tapp, C.3
  • 14
    • 84862846839 scopus 로고    scopus 로고
    • Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer
    • Yasuda H, de Figueiredo-Pontes LL, Kobayashi S et al. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J. Thorac. Oncol. 7, 1086-1090 (2012).
    • (2012) J. Thorac. Oncol. , vol.7 , pp. 1086-1090
    • Yasuda, H.1    De Figueiredo-Pontes, L.L.2    Kobayashi, S.3
  • 15
    • 84863338079 scopus 로고    scopus 로고
    • ROS1 rearrangements define a unique molecular class of lung cancers
    • Bergethon K, Shaw AT, Ou SH et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863-870 (2012).
    • (2012) J. Clin. Oncol. , vol.30 , pp. 863-870
    • Bergethon, K.1    Shaw, A.T.2    Ou, S.H.3
  • 16
    • 73949092289 scopus 로고    scopus 로고
    • An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis
    • Zillhardt M, Christensen JG, Lengyel E. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia 12, 1-10 (2010).
    • (2010) Neoplasia , vol.12 , pp. 1-10
    • Zillhardt, M.1    Christensen, J.G.2    Lengyel, E.3
  • 17
    • 84863786449 scopus 로고    scopus 로고
    • Anti-tumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification
    • Okamoto W, Okamoto I, Arao T et al. Anti-tumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol. Cancer Ther. 11, 1557-1564 (2012).
    • (2012) Mol. Cancer Ther. , vol.11 , pp. 1557-1564
    • Okamoto, W.1    Okamoto, I.2    Arao, T.3
  • 18
    • 84555190809 scopus 로고    scopus 로고
    • MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib
    • Lennerz JK, Kwak EL, Ackerman A et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J. Clin. Oncol. 29, 4803-4810 (2011).
    • (2011) J. Clin. Oncol. , vol.29 , pp. 4803-4810
    • Lennerz, J.K.1    Kwak, E.L.2    Ackerman, A.3
  • 19
    • 84862776792 scopus 로고    scopus 로고
    • HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis
    • Shojaei F, Simmons BH, Lee JH et al. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. Cancer Lett. 320, 48-55 (2012).
    • (2012) Cancer Lett. , vol.320 , pp. 48-55
    • Shojaei, F.1    Simmons, B.H.2    Lee, J.H.3
  • 20
    • 33748286819 scopus 로고    scopus 로고
    • Integrin-regulated FAK-Src signaling in normal and cancer cells
    • DOI 10.1016/j.ceb.2006.08.011, PII S0955067406001220
    • Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell. Biol. 18, 516-523 (2006). (Pubitemid 44332916)
    • (2006) Current Opinion in Cell Biology , vol.18 , Issue.5 , pp. 516-523
    • Mitra, S.K.1    Schlaepfer, D.D.2
  • 21
    • 71849120012 scopus 로고    scopus 로고
    • Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification
    • Yoshida T, Okamoto I, Okamoto W et al. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci. 101, 167-172 (2010).
    • (2010) Cancer Sci. , vol.101 , pp. 167-172
    • Yoshida, T.1    Okamoto, I.2    Okamoto, W.3
  • 22
    • 79551709762 scopus 로고    scopus 로고
    • Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer
    • Sen B, Peng S, Saigal B et al. Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin. Cancer Res. 17, 514-524 (2011).
    • (2011) Clin. Cancer Res. , vol.17 , pp. 514-524
    • Sen, B.1    Peng, S.2    Saigal, B.3
  • 24
    • 0025238437 scopus 로고
    • The protein Id: A negative regulator of helix-loop-helix DNA binding proteins
    • Benezra R, Davis RL, Lockshon D et al. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61, 49-59 (1990).
    • (1990) Cell , vol.61 , pp. 49-59
    • Benezra, R.1    Davis, R.L.2    Lockshon, D.3
  • 25
    • 79851510244 scopus 로고    scopus 로고
    • The stem cell gene 'inhibitor of differentiation 1' (ID1) is frequently expressed in non-small cell lung cancer
    • Rothschild SI, Kappeler A, Ratschiller D et al. The stem cell gene 'inhibitor of differentiation 1' (ID1) is frequently expressed in non-small cell lung cancer. Lung Cancer 71, 306-311 (2011).
    • (2011) Lung Cancer , vol.71 , pp. 306-311
    • Rothschild, S.I.1    Kappeler, A.2    Ratschiller, D.3
  • 26
    • 84866541922 scopus 로고    scopus 로고
    • MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma
    • Rothschild SI, Tschan MP, Federzoni EA et al. MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. Oncogene 31, 4221-4232 (2012).
    • (2012) Oncogene , vol.31 , pp. 4221-4232
    • Rothschild, S.I.1    Tschan, M.P.2    Federzoni, E.A.3
  • 27
    • 84862856363 scopus 로고    scopus 로고
    • MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma
    • Rothschild SI, Tschan MP, Jaggi R et al. MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma. J. Thorac. Oncol. 7, 1069-1077 (2012).
    • (2012) J. Thorac. Oncol. , vol.7 , pp. 1069-1077
    • Rothschild, S.I.1    Tschan, M.P.2    Jaggi, R.3
  • 28
    • 0035710746 scopus 로고    scopus 로고
    • -ΔΔCT method
    • DOI 10.1006/meth.2001.1262
    • Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408 (2001). (Pubitemid 34164012)
    • (2001) Methods , vol.25 , Issue.4 , pp. 402-408
    • Livak, K.J.1    Schmittgen, T.D.2
  • 29
    • 67649396221 scopus 로고    scopus 로고
    • The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells
    • Purnell PR, Mack PC, Tepper CG et al. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J. Thorac. Oncol. 4(4), 448-454 (2009).
    • (2009) J. Thorac. Oncol. , vol.4 , Issue.4 , pp. 448-454
    • Purnell, P.R.1    MacK, P.C.2    Tepper, C.G.3
  • 30
    • 84891746435 scopus 로고    scopus 로고
    • Major partial response to crizotinib a dual MET/ALK inhibitor in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement
    • Kohanka A, Barti-Juhasz H, Schönleber J et al. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung Cancer 83(1), 109-111 (2014).
    • (2014) Lung Cancer , vol.83 , Issue.1 , pp. 109-111
    • Kohanka, A.1    Barti-Juhasz, H.2    Schönleber, J.3
  • 31
    • 0242384942 scopus 로고    scopus 로고
    • Alternative Splicing of the Human Cyclin D-binding Myb-like Protein (hDMP1) Yields a Truncated Protein Isoform That Alters Macrophage Differentiation Patterns
    • DOI 10.1074/jbc.M307067200
    • Tschan MP, Fischer KM, Fung VS et al. Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns. J. Biol. Chem. 278, 42750-42760 (2003). (Pubitemid 37345884)
    • (2003) Journal of Biological Chemistry , vol.278 , Issue.44 , pp. 42750-42760
    • Tschan, M.P.1    Fischer, K.M.2    Fung, V.S.3    Pirnia, F.4    Borner, M.M.5    Fey, M.F.6    Tobler, A.7    Torbett, B.E.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.